Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide: A Randomized Clinical Trial
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Calcitonin gene-related peptide (CGRP) is a key neuropeptide in migraine pathophysiology and treatment. This study investigates whether CGRP administration can trigger aura in individuals with a diagnosis of migraine with aura.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:
• Age 18 to 65 years of age upon entry into screening
• History of migraine with aura for ≥ 12 months according to the International Classification of Headache Disorders 3rd Edition (ICHD-3) criteria
• ≥ 1 monthly day with aura that meets criteria as aura on average across the three months before screening
• Provision of informed consent prior to initiation of any study-specific activities/procedures.
Locations
Other Locations
Denmark
Rigshospitalet Glostrup
RECRUITING
Glostrup Municipality
Contact Information
Primary
Haidar Al-Khazali, MD
haidardk@hotmail.com
+4541598494
Backup
Hakan Ashina, MD, PhD
haakan.ashina@regionh.dk
+4528102495
Time Frame
Start Date: 2025-06-27
Estimated Completion Date: 2026-12-30
Participants
Target number of participants: 21
Treatments
Experimental: Calcitonin gene-related peptide (CGRP)
CGRP will be administered by intravenous infusion.
Placebo_comparator: Placebo
Placebo (isotonic saline) will be administered by intravenous infusion.
Related Therapeutic Areas
Sponsors
Leads: Danish Headache Center